menu ☰
menu ˟

Viralytics: Cavatak trial for late-stage melanoma reaches target enrollment

10 Jan 2014
Viralytics Limited announced it has achieved target enrollment in a phase 2 US trial of its proprietary formulation of Coxsackievirus A21 in treating late-stage melanoma patients.The 54th patient with late-stage melanoma was injected with Viralytics...

Click here to view the full article which appeared in Dermatology

IPH Logo